Verbalizing Extremes of the Visual Analogue Scale for Pruritus: A Consensus Statement

Masutaka Furue1, Toshiya Ebata2, Akihiko Ikoma1, Satoshi Takeuchi1, Yoko Kataoka1, Kenji Takamori1, Takahiro Satoh4, Hidehisa Saecki1, Matthias Augustin5, Adam Reich6, Jacek Szepietowski9, Alan Fleischer10, Christine Blome8, Ngoc Quan Phan11, Elke Weisshaar12, Gil Yosipovitch13 and Sonja Ständer11

1Department of Dermatology, Kyushu University, Maidashi 3-1-1, Higashiku, Fukuoka, 812-8582, 2Chitofuna Dermatology Clinic, Tokyo, Japan, 3Department of Dermatology, University of California, San Francisco, CA, USA, 4Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Osaka, Japan, 5Department of Dermatology, University of Lyon, Lyon, France, 6Department of Dermatology, University of Freiburg, Freiburg, Germany, 7Department of Dermatology, University of Göttingen, Göttingen, Germany, 8Department of Dermatology, University of Münster, Münster, Germany, 9Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland, 10Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USA, 11Competence Center Chronic Pruritus, Department of Dermatology, University Hospital Eppendorf, Eppendorf, Germany, 12Department of Dermatology, University Hospital Heidelberg, Germany, and 13Wake Forest Baptist Medical Center, Winston-Salem, NC, USA. E-mail: furue@dermatol.med.kyushu-u.ac.jp

We evaluated the importance of each item by assigning a weight score (maximum points, 10) to each. The 2 highest-ranked items were “itch intensity” (score, 10 ± 0) and “sleep disturbance” (9.3 ± 0.8), followed by “maximum score of itch” (7.3 ± 2.6), “itch frequency” (6.1 ± 1.8), “itch duration” (6 ± 2), “number of itch sites” (4.3 ± 2.6), “quality of life” (4.3 ± 2.7), “itch site” (3.7 ± 1.4) and “nature of itch” (3.3 ± 1.5).

We then discussed measurement tools for the two highest rank items, “itch intensity” and “sleep disturbance.” With respect to measuring “sleep disturbance (nocturnal itch intensity),” the discussion group reached an agreement that the VAS seemed to be a suitable scale, similar to the VAS for “itch intensity.” As for the terminology to be used to describe the 10-point end of the VAS, our 8 JSDACD members preferred the expressions “worst itch imaginable” for scoring “itch intensity” and “I cannot sleep at all” for scoring “sleep disturbance (nocturnal itch).”

These results were presented at the 6th World Congress of Itch in Brest, France, 2011. After the Congress, e-mail voting was proposed for the terminology of the 10-point end of the VAS, and this proposal was accepted by the members of the IFSI special interest group (TE, MA, JS, AF, CB, NQP, GY, SS). Twenty-six IFSI members from outside Japan participated in e-mail voting. With regard to the expression of the 10-point end of the VAS for “itch intensity,” “worst imaginable itch” was voted as the most suitable definition, including “worst itch imaginable” (n = 14). With regard to the expression of the 10-point end of the VAS for “sleep disturbance”, the expression “I cannot sleep at all” was selected as the suitable definition (n = 17) (Fig. 1).

CONSENSUS STATEMENT

Members of the Japanese Society for Dermatoallergology and Contact Dermatitis (JSDACD) (MF, TE, AI, ST, YK, KT, TS, and HS) discussed possible core items for evaluating pruritus in clinical settings, including clinical trials, in Japan. Nine items were proposed and we evaluated the importance of each item by assigning

---

**Fig. 1.** Visual analogue scale (VAS).
PERSPECTIVES

Our consensus is in line with the VAS for pain intensity, because recent publications suggest that both “worst imaginable pain” and “worst pain imaginable” seem to be frequently used expressions for the 10-point end of the VAS for pain intensity in various fields of medicine (9, 10). It is also in accordance with the labelled magnitude scale used in sensory psychophysics, where the end-point is “most intense sensation imaginable of any kind” (11). Further work is needed to test the comprehension and meaning of our proposed phrases against other contenders with patients and carers, and whether this varies across cultures and countries, especially when translated into other languages. In order to gain a wider consensus on our proposal, we intend to collaborate with other international groups, such as the Harmonising Outcome Measures for Eczema (HOME) initiative, which seeks to develop a core set of outcome measures for eczema that can be used in future clinical trials and record-keeping (12). Other topics to be further explored are: (i) Whether the VAS for “itch intensity” represents the mean itch intensity of only day-time, or both day- and night-time? (ii) Whether daily VAS assessments are more suitable than weekly ones? (iii) Should the subject be allowed to see his/her previous VAS score before deciding his/her current itch intensity? Based on the pain assessment study, Scott & Huskisson (13) recommended that prior scores should be made available to patients when serial measurements of pain are made in long-term experiments. Due to the presence of diverse clinical settings and trials, these items may be modified and adjusted appropriately by investigators.

The authors declare no conflicts of interest.

REFERENCES